C25 BioTelemetry Inc.

BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List

BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List

MALVERN, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100 Fastest-Growing Companies list for 2019. The ranking is based on the combination of revenue growth, earnings growth and the three-year annualized total return. It applies to U.S. publicly traded companies.

“Being recognized on Fortune’s 100 Fastest-Growing Companies list is a testament to the incredible work we are doing to deliver our life-saving technology and help improve quality of care,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry. “We are passionate about connecting people to solutions that save lives and are constantly evaluating opportunities that allow us to extend our reach and product offerings. Our continued growth reflects our focus, commitment and passion for the important work we do each day.”

BioTelemetry is advancing health by providing best-in-class technology and services that enable healthcare providers to remotely monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner. Today, BioTelemetry processes over four billion heartbeats per day, monitors over one million patients each year, supports some of the largest clinical trials and is pioneering patient-care monitoring by connecting people with their care teams. It is one of the largest, fastest growing and most profitable connected health companies.

To access the full list of companies, please visit: .

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original equipment manufacturing that serves both healthcare and clinical research customers. More information can be found at .

   
Contact: BioTelemetry, Inc.
  Heather C. Getz
  Investor Relations
  Executive Vice President, Chief Financial Officer
  800-908-7103
  
EN
03/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioTelemetry Inc.

Heartbeam Inc: 1 director

A director at Heartbeam Inc sold 250,000 shares at 3.580USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

 PRESS RELEASE

Philips to Acquire BioTelemetry

Philips to Acquire BioTelemetry Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac diagnostics and monitoring position outside the hospitalWith 2019 sales of USD 439 million, BioTelemetry annually monitors over 1 million cardiac patients remotely; its portfolio includes wearable heart monitors, AI-based data an...

 PRESS RELEASE

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results Posts Record Quarterly Revenue Amidst Rapid Recovery MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020. Quarter Highlights Recognized quarterly total revenue of $114.7 millionReached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19Reported quarterly GAAP net...

MarketLine Department
  • MarketLine Department

CardioComm Solutions, Inc. - Mergers & Acquisitions (M&A), Partnership...

Summary Marketline's CardioComm Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CardioComm Solutions, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdow...

 PRESS RELEASE

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on O...

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020 MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time. BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, .  The call will be archived on our website for at least two weeks. About BioTelemetryBioTelemetry, Inc. is the leading remote medical technology comp...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch